CurrentCignaPolicy N/A

Oncology (Oral - BRAF Inhibitor) - Zelboraf Prior Authorization Policy

Cigna prior authorization policy for outpatient prescription coverage of Zelboraf (vemurafenib) for FDA-approved and select guideline-supported oncology indications; applies to health benefit plans administered by Cigna companies.

Policy Summary

PayerCigna

PolicyOncology (Oral - BRAF Inhibitor) - Zelboraf Prior Authorization Policy

Policy CodePolicy N/A

Change TypeClinical criteria revisions and regimen additions

Effective DateN/A

Next Review DateN/A

Key ActionSubmit prior authorization with documentation of diagnosis, BRAF V600 mutation status, patient age, prior therapies when required, and intended regimen.

SourceLink

POLICY UPDATE CHANGES

Central Nervous System Cancer criteria: deleted requirement for age ≥ 3 years since Zelboraf is recommended for adjuvant therapy in patients < 3 years of age in guidelines.

Hairy Cell Leukemia criteria: added use of Zelboraf in combination with Gazyva (obinutuzumab) as an initial therapy option for patients unable to tolerate purine analogs.

Thyroid carcinoma example wording changed to include 'and oncocytic carcinoma (formerly Hürthle cell carcinoma)'.

Policy name changed from 'Oncology - Zelboraf PA Policy' to 'Oncology (Oral - BRAF Inhibitor) - Zelboraf PA Policy'.

1 yearApproval duration

≥18Minimum patient age

BRAF V600Required biomarker

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Policy overview

BRAF V600 (including V600E)

Required biomarkerBRAF V600 mutation (including V600E)

Applies toMost covered indications including Erdheim-Chester disease, melanoma, CNS cancers, histiocytic neoplasms, NSCLC, and differentiated thyroid carcinoma

Evidence sourcesFDA-approved indications and guideline-supported uses (see policy criteria) require documented BRAF V600 mutation-positive status

Approval duration

Standard approval duration1 year

Applies toAll covered FDA-approved and guideline-supported indications listed in policy

Authorization notePrior authorizations are issued for 1 year when criteria are met

Zelboraf (vemurafenib) is an oral BRAF inhibitor used to treat tumors harboring activating BRAF V600 mutations. This policy covers outpatient prescription benefit prior authorization for Zelboraf when used for FDA-approved indications (including Erdheim‑Chester disease and unresectable or metastatic melanoma) and for select guideline-supported oncology indications where evidence supports use. Coverage is biomarker-driven and generally requires documentation of BRAF V600 mutation-positive disease and other criteria specific to each indication.

Prior authorization is required for prescription benefit coverage; when criteria are met, approvals are generally provided for 1 year. The policy applies to health benefit plans administered by Cigna companies and aligns coverage to FDA-labeled uses and recognized guideline recommendations (for example, combination therapy with a MEK inhibitor where indicated).

Covered indications and medical necessity criteria

Covered indications and criteria

Covered when ALL of the following are met for each indication

Erdheim-Chester Disease (FDA-approved): Approve for 1 year if the patient meets BOTH of the following: A) Patient is >= 18 years of age; AND B) Patient has BRAF V600 mutation-positive disease.

Melanoma (FDA-approved): Approve for 1 year if the patient meets ALL of the following: A) Patient is >= 18 years of age; AND B) Patient has unresectable, advanced, or metastatic melanoma; AND C) Patient has BRAF V600 mutation-positive disease.

Central Nervous System Cancer (other use with supportive evidence): Approve for 1 year if the patient meets ALL of the following: A) The medication is being used for ONE of the following: i) Adjuvant treatment of one of: a) pilocytic astrocytoma; OR b) pleomorphic xanthoastrocytoma; OR c) circumscribed ganglioglioma, neuroglioma, or glioneuronal tumor; OR d) pediatric diffuse high-grade glioma; OR ii) Recurrent or progressive disease for one of: a) high-grade glioma; OR b) circumscribed glioma; OR c) glioblastoma; OR iii) Brain metastases due to melanoma; AND B) Patient has BRAF V600 mutation-positive disease; AND C) The medication is prescribed in combination with Cotellic (cobimetinib tablets).

Required biomarker testing

BRAF V600 (including V600E)

Biomarker requirementBRAF V600 mutation (including V600E) is required for approval for most covered indications (e.g., Erdheim-Chester disease, melanoma, CNS cancers, histiocytic neoplasms, NSCLC, differentiated thyroid carcinoma)

DocumentationPrior authorization requests must include documentation of BRAF V600 mutation-positive status

TestingMutation must be detected by an appropriate test as indicated in FDA labeling or guideline-recommended methods

BRAF V600 mutation-positive

DefinitionBRAF V600 mutation-positive: presence of an activating mutation at codon V600 of the BRAF gene (including V600E)

Clinical implication

What providers must submit / prior authorization rules

Prior Authorization

Prior Authorization Required

Prior authorization is required for Zelboraf (vemurafenib) prescription benefit coverage. Approvals are granted for 1 year. Submit a prior authorization request before dispensing to avoid claim denials.

Approval duration: 1 year
Required for FDA‑approved and supported off‑label indications listed in policy

Step Therapy

Step / Prior Therapy Requirement

For hairy cell leukemia (and other hematologic uses described under "Other Uses with Supportive Evidence"), the request must document that the patient is unable to tolerate or has an intolerance to purine analogs (for example, cladribine or pentostatin) AND that vemurafenib will be used in combination with rituximab or obinutuzumab when specified by the criteria. If these step/prior therapy requirements are not met, the request may be denied.

Step requirement example: intolerance or contraindication to purine analogs (e.g., cladribine, pentostatin)
Combination therapy requirement: used with rituximab or Gazyva (obinutuzumab) where indicated

Coding and approval details

Covered CPT Codesmixed

No codes listed

Approval duration

Standard approval duration (coding quick reference)1 year

ContextApplies to all covered indications when policy criteria are met

Authorization practiceAuthorizations are provided for one year and require appropriate documentation of diagnosis and biomarker status

Line of therapy considerations

first-line | second-line

Line of therapy notes: NCCN lists Zelboraf as first-line or subsequent therapy for some indications (eg NSCLC, melanoma combination preferred); policy covers both FDA-approved and guideline-supported uses per criteria.

Clinical background and scope

Vemurafenib selectively targets tumors with activating BRAF V600 mutations and is used as monotherapy or in combination with a MEK inhibitor (cobimetinib) depending on the tumor type and guideline recommendations. Covered indications include FDA‑approved uses such as Erdheim‑Chester disease and advanced melanoma, and selected off‑label, evidence‑supported indications (for example certain central nervous system tumors, hairy cell leukemia in specified circumstances, histiocytic neoplasms, BRAF V600E non‑small cell lung cancer, and radioiodine‑refractory differentiated thyroid carcinoma) when the policy’s criteria are met.

For hairy cell leukemia, coverage may require prior trial of another systemic therapy or use in combination with an anti‑CD20 antibody (rituximab or obinutuzumab) when purine analogs cannot be tolerated. For many indications, the medication is intended for patients aged ≥18 years unless the specific criteria indicate otherwise, and BRAF V600 mutation-positive status is required for most covered uses.

Policy changes and updates

2025-08-20Annual revisionLatest

Central Nervous System Cancer: deleted requirement for age ≥ 3 years for adjuvant use per guideline recommendations; Hairy Cell Leukemia: added criteria allowing Zelboraf in combination with obinutuzumab (Gazyva) as initial therapy for patients unable to tolerate purine analogs.

2024-08-14Annual revision

Central Nervous System Cancer: clarified adjuvant treatment examples to specify circumscribed ganglioglioma/neuroglioma/glioneuronal tumor and added pediatric diffuse high-grade glioma; recurrent/progressive disease language updated.

2023-07-19Annual revision

Policy Summary

PayerCigna

PolicyOncology (Oral - BRAF Inhibitor) - Zelboraf Prior Authorization Policy

Policy CodePolicy N/A

Change TypeClinical criteria revisions and regimen additions

Effective DateN/A

Next Review DateN/A

Key ActionSubmit prior authorization with documentation of diagnosis, BRAF V600 mutation status, patient age, prior therapies when required, and intended regimen.

SourceLink

On This Page

Adjuvant indication no longer restricted to >= 3 years of age per policy history.

Hairy Cell Leukemia (other use with supportive evidence): Approve for 1 year if the patient meets BOTH of the following: A) Patient is >= 18 years of age; AND B) Patient meets ONE of the following: i) Patient has tried at least one other systemic therapy for hairy cell leukemia (examples include cladribine, pentostatin, rituximab, interferon alpha-2b); OR ii) Patient meets BOTH: a) Patient is unable to tolerate purine analogs (eg active infection, frail); AND b) Zelboraf is used in combination with rituximab or Gazyva (obinutuzumab intravenous infusion).

Histiocytic Neoplasm (other use with supportive evidence): Approve for 1 year if the patient meets ALL of the following: A) Patient is >= 18 years of age; AND B) Patient has Langerhans cell histiocytosis; AND C) Patient has BRAF V600 mutation-positive disease.

For Erdheim-Chester disease refer to FDA-approved indication.

Non-Small Cell Lung Cancer (other use with supportive evidence): Approve for 1 year if the patient meets BOTH of the following: A) Patient is >= 18 years of age; AND B) Patient has BRAF V600E mutation-positive disease.

Differentiated Thyroid Carcinoma (other use with supportive evidence): Approve for 1 year if the patient meets ALL of the following: A) Patient is >= 18 years of age; AND B) Patient has differentiated thyroid carcinoma (eg papillary, follicular, oncocytic); AND C) Disease is refractory to radioactive iodine therapy; AND D) Patient has BRAF mutation-positive disease.

Regimen	Indication / Notes	Coverage status
Zelboraf (vemurafenib) monotherapy	BRAF V600–mutated tumors when monotherapy is appropriate (eg when combination with a MEK inhibitor is contraindicated)
Zelboraf (vemurafenib) + Cotellic (cobimetinib)	Recommended for BRAF V600–mutated melanoma and supported by guidelines for CNS cancers and other indications where BRAF/MEK combination therapy is indicated; policy requires combination with Cotellic for CNS indications per criteria
Zelboraf (vemurafenib) in combination with an anti‑CD20 antibody (rituximab or obinutuzumab [Gazyva])	Specifically supported for hairy cell leukemia in patients unable to tolerate purine analogs (eg frail or with active infection); guidelines list Zelboraf ± rituximab for relapsed/refractory disease and add Zelboraf + anti‑CD20 as an initial option for patients not candidates for purine analogs

Zelboraf is considered not medically necessary for any uses not explicitly listed in this policy. Criteria will be updated as new published data become available.

Any uses other than the listed FDA‑approved indications and those specific, guideline‑supported uses described in this policy are not medically necessary and are not covered under the prescription benefit.

Required for approval across specified indications such as Erdheim-Chester disease and unresectable/metastatic melanoma

Associated requirementMust be documented in the prior authorization submission per policy criteria

Documentation Required

Required Documentation for Prior Authorization

Include the following documentation with the prior authorization request to support medical necessity: diagnosis and indication (including disease subtype), patient age, documentation of BRAF V600 or BRAF V600E mutation status when required by the indication, prior therapy history (including intolerance or contraindication to purine analogs when applicable), planned concomitant therapies (e.g., rituximab or obinutuzumab), and rationale for use if the request is for a non‑FDA but supported indication.

Diagnosis and clinical indication
Patient age
BRAF mutation test result (e.g., V600/V600E)
Prior therapy details and intolerance documentation (if claiming inability to tolerate purine analogs)
Planned combination therapy (if applicable)
Supporting clinical rationale for off‑label uses

Denial Risk

Denial Triggers / Billing Risks

Requests lacking required documentation, requests for uses not listed as covered or supported by evidence, or claims submitted without prior authorization when required will be denied. Claims for indications explicitly stated as not medically necessary will be denied. Ensure correct billing codes and mutation testing documentation are included to avoid denial.

Denial triggers: missing prior authorization when required
Denial triggers: absent or incomplete BRAF mutation result
Denial triggers: lack of documented prior therapy/intolerance when step therapy is required
Denial triggers: request for indications listed under "Conditions Not Covered"

Central Nervous System Cancer: deleted age ≥3 years restriction for adjuvant indication to align with guideline recommendations.

2025-04-08Update

Policy name changed from 'Oncology - Zelboraf PA Policy' to 'Oncology (Oral - BRAF Inhibitor) - Zelboraf PA Policy'.